Elafibranor - GFT505

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 2727

CAS [923978-27-2]

MF C22H24O4S
MW 384.49

  • Purity: 98%
  • Soluble in 0.1N NaOH(aq) and DMSO



The dual PPARα/δ agonist Elafibrinor (GFT505) (EC50 values of 45 nM and 175 nM for PPARα and PPARδ, respectively) is a liver-targeted insulin-sensitizer that is a drug candidate for the treatment of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NAS). In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms.

KEYWORDS: Elafibranor | supplier | PPAR α/δ agonist | GFT505 | GFT 505 | GFT-505 | CAS [923978-27-2] | Metabolism | PPAR | Agonist | Receptors | Insulin | Diabetes | NAFLD | NAS | Steatohepatitis | Peroxisome Proliferator-activated Receptor

Size Unit Price Stock
10 mg €90.00 In Stock
50 mg €270.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...